Biomedical Engineering Reference
In-Depth Information
160. Bookman MA, Godfrey S, Padavic K, Griffin T, Corda JP,
Hamilton TC, et al. (1990) Anti-transferrin receptor immu-
notoxin (IT) therapy: Phase I intraperitoneal (i.p.) trial. Proc.
ASCO 9, 187.
161. Cohen KA, Liu T, Bissonette R, Puri RK, Frankel AE. (2003)
DAB389EGF fusion protein therapy of refractory glioblas-
toma multiforme. Curr. Pharm. Biotechnol. 4, 39-49.
162. Frankel AE, Powell BL, Hall PD, Case LD, Kreitman RJ.
(2002) Phase I trial of a novel diphtheria toxin/granulocyte
macrophage colony-stimulating factor fusion protein
(DT388GMCSF) for refractory or relapsed acute myeloid
leukemia. Clin. Cancer Res. 8, 1004-1013.
163. Grossbard ML, Multani PS, Freedman AS, O'Day S,
Gribben JG, Rhuda C, et al. (1999) A Phase II study of
adjuvant therapy with anti-B4-blocked ricin after autolo-
gous bone marrow transplantation for patients with
relapsed B-cell non-Hodgkin's lymphoma. Clin. Cancer
Res. 5, 2392-2398.
164. Messmann RA, Vitetta ES, Headlee D, Senderowicz AM,
Figg WD, Schindler J, et al. (2000) A Phase I study of
combination therapy with immunotoxins IgG-HD37-degly-
cosylated ricin A chain (dgA) and IgG-RFB4-dgA (Combo-
tox) in patients with refractory CD19(
þ
), CD22(
þ
) B cell
lymphoma. Clin. Cancer Res. 6, 1302-1313.
165. LeMaistre CF, Saleh MN, Kuzel TM, Foss F, Platanias LC,
Schwartz G, et al. (1998) Phase I trial of a ligand fusion-
protein (DAB389IL-2) in lymphomas expressing the receptor
for interleukin-2. Blood 91, 399-405.
166. Foss FM, Bacha P, Osann KE, Demierre MF, Bell T, Kuzel T.
(2001) Biological correlates of acute hypersensitivity events
with DAB(389)IL-2 (denileukin diftitox, Ontak
1
) in cutane-
ous T-cell lymphoma: decreased frequency and severity with
steroid premedication. Clin. Lymphoma 1, 298-302.
167. Ho VT, Zahrieh D, Hochberg E, Micale E, Levin J, Reynolds
C, et al. (2004) Safety and efficacy of denileukin diftitox in
patients with steroid-refractory acute graft-versus-host dis-
ease after allogeneic hematopoietic stem cell transplantation.
Blood 104, 1224-1226.
168. Shaughnessy PJ, Bachier C, Grimley M, Freytes CO,
Callander NS, Essell JH, et al. (2005) Denileukin diftitox
for the treatment of steroid-resistant acute graft-versus-host
disease. Biol. Blood Marrow Transplant. 11, 188-193.
169. Frankel AE, Fleming DR, Hall PD, Powell BL, Black JH,
Leftwich C, et al. (2003) A Phase II study of DT
fusion protein denileukin diftitox in patients with fludarabine-
refractory chronic lymphocytic leukemia. Clin. Cancer Res.
9, 3555-3561.
170. Morgan SJ, Seymour JF, Prince HM, Westerman DA, Wolf
MM. (2004) Confirmation of the activity of the interleukin-2
fusion toxin denileukin diftitox against chemorefractory
chronic lymphocytic leukemia, including cases with chromo-
some 17p deletions and without detectable CD25 expression.
Clin. Cancer Res. 10, 3572-3575.
171. Frankel AE, Surendranathan A, Black JH, White A, Ganjoo
K, Cripe LD. (2006) Phase II clinical studies of denileukin
diftitox diphtheria toxin fusion protein in patients with
previously treated chronic lymphocytic leukemia. Cancer
106, 2158-2164.
172. Bagel J, Garland WT, Breneman D, Holick M, Littlejohn TW,
Crosby D, et al. (1998) Administration of DAB389IL-2 to
patients with recalcitrant psoriasis: a double-blind, Phase II
multicenter trial. J. Am. Acad. Dermatol. 38, 938-944.
173. Foss F, Demierre MF, DiVenuti G. (2005) A Phase-1 trial of
bexarotene and denileukin diftitox in patients with relapsed or
refractory cutaneous T-cell lymphoma. Blood 106, 454-457.
174. Dang NH, Hagemeister FB, Pro B, McLaughlin P,
Romaguera JE, Jones D, et al. (2004) Phase II study of
denileukin diftitox for relapsed/refractory B-Cell non-
Hodgkin's lymphoma. J. Clin. Oncol. 22, 4095-4102.
175. Dang NH, Fayad L, McLaughlin P, Romaguara JE,
Hagemeister F, Goy A, et al. (2007) Phase II trial of the
combination of denileukin diftitox and rituximab for
relapsed/refractory B-cell non-Hodgkin lymphoma. Br. J.
Haematol. 138, 502-505.
176. Kuzel TM, Li S, Eklund J, Foss F, Gascoyne R, Abramson N,
et al. (2007) Phase II study of denileukin diftitox for previ-
ously treated indolent non-Hodgkin lymphoma: final results
of E1497. Leuk. Lymphoma 48, 2397-2402.
177. Gerena-Lewis M, Crawford J, Bonomi P, Maddox AM,
Hainsworth J, McCune DE, et al. (2009) A Phase II trial
of denileukin diftitox in patients with previously treated
advanced non-small cell lung cancer. Am. J. Clin. Oncol.
32, 269-273.
178. LeMaistre CF, Meneghetti C, Rosenblum M, Reuben J,
Parker K, Shaw J, et al. (1992) Phase I trial of an interleu-
kin-2 (IL-2) fusion toxin (DAB486IL-2) in hematologic
malignancies expressing the IL-2 receptor. Blood 79,
2547-2554.
179. Tepler I, Schwartz G, Parker K, Charette J, Kadin ME,
Woodworth TG, et al. (1994) Phase I trial of an interleu-
kin-2 fusion toxin (DAB486IL-2) in hematologic malignan-
cies: complete response in a patient with Hodgkin's disease
refractory to chemotherapy. Cancer 73, 1276-1285.
180. Hesketh P, Caguioa P, Koh H, Dewey H, Facada A,
McCaffrey R, et al. (1993) Clinical activity of a cytotoxic
fusion protein in the treatment of cutaneous T-cell lymphoma.
J. Clin. Oncol. 11, 1682-1690.
181. LeMaistre CF, Craig FE, Meneghetti C, McMullin B, Parker
K, Reuben J, et al. (1993) Phase I trial of a 90-minute infusion
of the fusion toxin DAB486IL-2 in hematological cancers.
Cancer Res. 53, 3930-3934.
182. Platanias LC, Ratain MJ, O'Brien S, Larson RA, Vardiman
JW, Shaw JP, et al. (1994) Phase I trial of a genetically
engineered interleukin-2 fusion toxin (DAB486IL-2) as a
6 hour intravenous infusion in patients with hematologic
malignancies. Leuk. Lymphoma 14, 257-262.
183. Foss FM, Borkowski TA, Gilliom M, Stetler-Stevenson M,
Jaffe ES, Figg WD, et al. (1994) Chimeric fusion protein
toxin DAB486IL-2 in advanced mycosis fungoides and
the Sezary syndrome: correlation of activity and interleu-
kin-2 receptor expression in a Phase II study. Blood 84,
1765-1774.
Search WWH ::
Custom Search